冠心病心衰患者经参麦注射液治疗前后血浆不对称二甲基精氨酸浓度变化

Effect of Shenmai Injection on Plasma Asymmetric Dimethylarginine Level in Patients with Coronary Artery Disease and Chronic Heart Failure

目的探讨参麦注射液治疗冠心病心衰患者前后血浆不对称二甲基精氨酸(ADMA)浓度变化,并观察参麦注射液治疗的临床疗效。方法100例冠心病心衰患者随机分为参麦治疗组和常规治疗组,常规治疗组接受常规治疗,参麦治疗组在常规治疗的同时加用参麦注射液,治疗前后检测血浆ADMA水平,并观察临床疗效,同时检测44例健康体检者为对照组。结果冠心病心衰患者血浆ADMA明显高于对照组(P<0.001),治疗前参麦治疗组与常规治疗组血浆ADMA差别不显著(P>0.05),治疗后两组血浆ADMA浓度都显著下降(P<0.05),且参脉治疗组显著低于常规治疗组(P<0.05)。参脉治疗组显效率高于常规治疗组(P<0.05)。结论冠心病心衰患者血浆ADMA浓度增高,心衰纠正后其浓度下降,加用参麦注射液不仅更能有效降低血浆ADMA浓度,而且疗效更佳。

Objective To investigate the effect of Shenmal injection on plasma asymmetric dimethylarginine （ADMA） level in patients with coronary artery disease and chronic heart failure and to detect the clinical efficacy of Shenmal injection in treatment of them. Methods One hundred patients with coronary heart disease and chronic heart failure were randomized to receive routine treatment or additional Shenmai injection treatment. Clinical improvement and plasma ADMA were monitored and compared and 44 healthy volunteers were served as the blank control. Results The plasma ADMA levels were significantly higher in the patients as compared with the blank controls （P〈 0. 001 ） and were significantly reduced in both groups after treatment （P〈 0.05）. Before the treatment there was no remarkable difference of the concentrations of plasma ADMA in both treatment groups （P〉 0.05）, but after treatment the concentrations of plasma ADMA were significantly lower in the shenmai injection treatment group than that of the routine treatment group （P〈 0.05）. The clinical efficacy was significantly better in the shenmai injection treatment group than that of the routine treatment group （P〈 0.05）. Conclusions The plasma ADMA levels are increased in patients with coronary heart diseases and chronic heart failure and reduced after treatment. Shenmai injection effectively decreases the plasma ADMA levels accompanied with significantly better clinical therapeutic effects in patients with coronary heart diseases and chronic heart failure.